<< 1 >> 



CicloMed Announces FDA Clearance of IND Application for Ciclopirox Prodrug in the Treatment of Bladder Cancer
Published: 10/11/2017

CicloMed LLC announced that its development candidate for non-muscle-invasive and muscle-invasive bladder cancer, Ciclopirox Prodrug, was cleared by the U.S. Food and Drug Administration to begin human clinical trials. With this clearance, CicloMed plans to initiate the first-in-human safety trial in patients with advanced solid tumor cancers as soon as possible at several centers, including The University of Kansas Cancer Center.

The University of Kansas Cancer Center receives renewal of National Cancer Institute Designation and Announces Consortium Partnership
Published: 8/3/2017

The University of Kansas Cancer Center announced that the National Cancer Institute (NCI) renewed its national cancer center designation for five years and that Children’s Mercy has been formally approved as a cancer center consortium partner. The KU Cancer Center remains one of only 71 nationally designated centers by the National Cancer Institute, a part of the National Institutes of Health

<< 1 >> 

News


Browse by Year
2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

Expert Care

find a doctor

U.S. News and World Reports 2019-2020